NCT01368042

Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 265 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol intravenous (iv).

Detailed description

The scientific purpose of this study is to obtain data on the use of paricalcitol iv in real-life clinical practice and the effect it has on participant health-related QoL. In this study, paricalcitol iv will be prescribed on an on-label basis in an everyday setting. The RAND 36-Item Health Survey results will be collected for a 6-month period (every 3 months) in order to assess the effect of paricalcitol iv on participant health-related QoL.

Conditions

• Chronic Kidney Disease
• Secondary Hyperparathyroidism

Timeline

• Start date: 2011-08-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2011-06-07
• Last updated: 2014-08-01
• Results posted: 2014-07-24

Locations

11 sites across 1 country: Greece